Introduction
============

Embryonic stem cells (ESCs) are derived from the inner cell mass of preimplantation blastocysts, with unlimited self-renewal capacity. These pluripotent cells can differentiate into various cell types representing all the three germ layers to participate in development and formation of an adult body ([@ref-8]; [@ref-21]). A better understanding of the molecular mechanisms regulating ESCs property is inevitably and urgently required to exploit their utilization toward full potential and safety. In vitro cultured ESCs are ready to switch from self-renewal state to multi-differentiation during their proliferation. Fate determination of ESCs is regulated by the cross-talk between extraneous stimulus signals and interior gene expression profile ([@ref-31]; [@ref-20]; [@ref-34]; [@ref-11]; [@ref-35]). Self-renewal is intrinsically associated with cell cycle control. The cell cycle in pluripotent ESCs is governed by unique mechanisms that support unrestricted proliferation and competency for appropriate differentiation. As the choice between self-renewal and differentiation, the pluripotency state of ESCs is stabilized by an integration of stimulus upon interconnected network of pluripotency factors ([@ref-4]; [@ref-31]; [@ref-11]; [@ref-24]; [@ref-45]). Pluripotency factors, especially OCT4, Nanog, and SOX2, play central roles in controlling self-renewal and preventing onset of differentiation. The down-regulation of these three core pluripotency factors induces ESCs differentiation ([@ref-9]; [@ref-33]; [@ref-49]). The self-renewal activity of ESCs is directly connected with their unique short G~1~ phase, and most cells are in S phase at any given time ([@ref-36]; [@ref-43]). Expression changes of cell-cycle regulatory proteins and cell-cycle structure were demonstrated to be associated with differentiation initiation. Factors controlling the cell cycle progress might be necessary to maintain pluripotency upon block differentiation ([@ref-42]). Common regulation genes and pathways were suggested in both cell cycle and self-renewal activities by recent literature ([@ref-44]; [@ref-51]). Many cell cycle related factors were detected under regulation of pluripotency factors such as OCT4, SOX2, Nanog, and Lin28, including CDK1, cyclin D1, CDK6, CDC25A, CDC7, cyclinA, cyclinB, and CDK4 ([@ref-1]; [@ref-50]; [@ref-12]; [@ref-32]).

It is well-documented that mouse ESCs (mESCs) retain self-renewal and pluripotency in the presence of leukaemia inhibitory factor (LIF) and bone morphogenetic protein-4 ([@ref-11]; [@ref-13]; [@ref-47]). LIF-LIFR/gp130-JAK-STAT3 pathway provides activation of pluripotency factors expression and down-regulation of differentiation related genes ([@ref-47]; [@ref-3]; [@ref-25]; [@ref-11]). However, the precise mechanisms coordinating cell fate determination and pluripotency remain poorly understood. It is not fully uncovered how the balance between self-renewal and differentiation is regulated.

Epidermal growth factor receptor (EGFR) plays critical roles in many cellular progresses, including proliferation, differentiation and apoptosis ([@ref-32]). EGFR was reported to be the upstream regulator critical for STAT3 phosphorylation in cancer cells and cancer stem- like cells ([@ref-5]; [@ref-29]; [@ref-38]). EGFR and its ligand EGF were reported to be highly expressed in embryos, and EGFR knockout in mice led to preimplantation death of the embryos, suggesting that the EGF-EGFR system might be related to early embryo development in an autocrine and/or paracrine manner ([@ref-15]; [@ref-18]; [@ref-28]; [@ref-6]). RNA interference assay demonstrated that down-regulation of EGFR and EGF expression impaired survival of embryos and delayed implantation ([@ref-7]). The role of EGFR in mESCs still remains poorly understood. In this study, chemical inhibitors of EGFR and RNA interference were adopted to investigate the effect of EGFR deficiency on mESCs self-renewal and pluripotency, and a RNA-seq was used to demonstrate the global gene expression change in EGFR deficient mESCs.

Materials and Methods
=====================

Cell culture and experimental design
------------------------------------

E14.1 mESC (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA), supplemented with one mM sodium bicarbonate (Gibco), 1% penicillin/streptomycin (Gibco), two mM L-glutamine (Gibco), 1% MEM non-essential amino acids (Gibco), 0.1 mM β-mercaptoethanol (Sigma, Darmstadt, Germany), 1,000 U/ml mouse LIF (Millipore, Darmstadt, Germany), one μM PD0325901 (Selleck, Houston, TX, USA), three μM CHR99021 (Selleck), and 15% (v/v) ES cell-qualified fetal bovine serum (Millipore). Cells were cultured on 0.1% gelatin coated 6-well plate at a density of 10^6^ cells per well, at 37 °C and an atmosphere of 5% CO~2~. For embryoid body (EB) formation, cells were cultured in drop-culture method with a 25 μl drop containing 1,000 cells, without LIF and 2i (PD0325901 and CHR99021). Cells were divided into two groups, EGFR inhibition group and control group. For EGFR inhibition group, mESCs were treated with 5, 10, 15, and 20 μΜ AG1478 (Selleck) for 24 h, and the concentration of 10 μΜ was the most suitable ([Figs. S2A](#supp-1){ref-type="supplementary-material"}--[S2E](#supp-1){ref-type="supplementary-material"}). Additionally, mESCs were treated with 0.05, 0.5, 5, and 10 μΜ gefitinib (Selleck) for 24 h, and the concentration of five μΜ was the most suitable ([Fig. S3A](#supp-1){ref-type="supplementary-material"}). The stock solution for inhibitors used were prepared in dimethyl sulfoxide.

Cell proliferation assay and cell cycle analysis
------------------------------------------------

Mouse ESCs were seeded in 0.1% gelatin coated 96-well plates at a cell density of 5 × 10^3^ per well with treatment of AG1478 or not. Cell Counting kit-8 Kit (CCK-8) (Dojindo Molecular Technologies, Rockville, MD, USA) was used to compare cell proliferation according to the manufacturer's instructions. Cells were fixed in 70% ice-cold ethanol at 4 °C overnight, then incubated with 0.1 mg/ml RNase A (Sigma) for 30 min followed by incubation with 100 μg/ml propidium iodide (PI) (Sigma) staining for 5 min at room temperature and avoid light condition. Cell-cycle analysis was performed immediately using flow cytometry.

Alkaline phosphatase staining
-----------------------------

Expression of alkaline phosphatase (AP) was detected by staining with an AP detection kit (Stemgent, Cambridge, MA, USA) following manufacturer's instructions.

Immunofluorescence
------------------

Cells were fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. To detect intracellular antigens, cells should be permeabilized with 0.1% Triton X-100 after fixation. Cells were then blocked by 5% BSA in PBS at room temperature for 30 min, and were incubated with primary antibodies for EGFR (1:500; CST, Danvers, MA, USA), SSEA-1 (1:500; Santa Cruz Biotechnology, Dallas, TX, USA), OCT4 (1:500; CST), and Nanog (1:500; CST) overnight at 4 °C. Cells were incubated with fluorescence-conjugated secondary antibodies for 1 h at room temperature and avoid from light. Nuclei were stained with 4′,6-diamidino-2-phenylindole, Fluorescence signals were detected with a fluorescence microscope.

Western blotting
----------------

Cells were lysed using T-PER^®^ Protein Extraction Reagent (Thermo-Fisher, Waltham, MA, USA) containing protease inhibitor cocktail (Roche, Basel, Switzerland). Equal amount (30 μg per lane) of denatured proteins were separated by SDS--PAGE and transferred to nitrocellulose membranes (Millipore). Then membranes were blocked with 5% non-fat milk for 2 h at room temperature, and then incubated with the primary antibodies (CST) of recommended concentration diluted in 5% non-fat milk overnight at 4 °C. HRP-conjugated anti-rabbit IgG was used as secondary antibody and the blots were developed using the Pierce ECL Western Blotting Substrate according to the manufacturer's instructions (Pierce, Appleton, WI, USA). The visualized bands were quantified by calculating net light density value with Gel Image System 1D software (v4.2), based on a Tanon-5200 Chemiluminescent Imaging System (Shanghai, China).

Targeting knock-down assays
---------------------------

For transient short interfering RNA (siRNA) transfection, cells at 70% confluence were transfected using Lipofectamine^®^ RNAiMAX (Thermo-Fisher, Waltham, MA, USA) in complete medium according to the manufacturer's instructions, with a final siRNA concentration of 100 nM. The siRNAs were incubated with Lipofectamine^®^ RNAiMAX reagent for approximately 20 min and diluted with Opti-MEM^®^ medium. The siRNA-lipid complex was gently added to the culture medium. A total of 6 h later, the culture medium was replaced with fresh medium. A total of 48 h after transfection cells were trypsinized and plated for the different experiments. siRNAs were purchased from GenePharma (<http://www.genepharma.com/>). siRNA sequences were as follows: EGFR siRNA-1: 5′-CUGUGCGAUUCAGCAACAA-3′; EGFR siRNA-2: 5′-CCACCUAUCAGAUGGAUGU-3′; EGFR siRNA-3: 5′-CCCUGUCGCAAAGUUUGUA-3′; EGFR siRNA-4: 5′-GUGCUACGCAAACACAAUA-3′; and control non-targeting siRNA-NC: 5′-UUCUCCGAACGUGUCACGU-3′.

RNA preparation, libraries sequencing, and reads mapping
--------------------------------------------------------

Total RNAs were isolated from mESCs in EGFR inhibition group and control group, using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA degradation and contamination was monitored by 1% agarose gels. RNA purity was checked by NanoDrop ND-1000 spectrophotometer (IMPLEN, Westlake Village, CA, USA). RNA integrity was assessed using RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA). A total amount of three μg RNA of each mESCs sample (from EGFR inhibition group or control group) was used to construct cDNA library for RNA-seq analysis, after ribosomal RNA removal. Subsequently, sequencing libraries were generated using the rRNA-depleted RNA by NEBNext^®^ Ultra™ Directional RNA Library Prep Kit for Illumina^®^ (NEB, Ipswich, MA, USA). The constructed libraries were sequenced on an Illumina HiSeq2500 platform (FC-104-5001; Illumina, San Diego, CA, USA). The RNA-seq experiments were performed by Experimental Department of Novogene Corporation (Beijing, China).

Clean reads were obtained from raw reads after the removal of reads containing an adapter, reads with low quality, and reads containing ploy-N. At the same time, Q20, Q30, and GC content were calculated for the clean dataset. All the down stream analyses were based on the clean data. Clean reads were aligned to the mouse genome mm10 by Tophat 2.0.3 ([@ref-16]) with default parameters. Only the uniquely mapped reads were used for future expression analysis. HTSeq quantified RNAs based on annotation with the union model, and distributed reads into different known types of genes.

Gene expression and functional annotation
-----------------------------------------

The mapped reads of each sample were assembled by both Scripture (beta2) ([@ref-10]) and Cufflinks software (v2.1.1) ([@ref-41]) in a reference-based approach. Cufflinks was used to calculate fragments per-kilo-base of exon per million fragments mapped (FPKM) of genes in each sample to quantify their expression levels. Based on FPKM of each replicate, Pearson's correlation coefficient (*R*^2^) was calculated to measure the correlation between two variables. Cuffdiff (<http://cole-trapnell-lab.github.io/cufflinks/>) was used to identify significant differentially expressed genes (DEGs) between the two mESCs groups, and corrected *P*-value \<0.05 was set as the threshold for DEGs. Among these DEGs, nine protein coding genes were randomly selected for quantitative PCR to validate the mRNAs expression results from RNA-seq, and data are presented as the log~2~ fold change between EGFR inhibition and control mESCs.

Differentially expressed genes were classified according to gene ontology (GO) enrichment analysis and kyoto encyclopedia of genes and genomes (KEGG) analysis. The GO categories were derived from (<http://www.geneontology.org>), and GO enrichment of DEGs was implemented by the GO seq R package ([@ref-17]; [@ref-30]; [@ref-48]) in which gene length bias was corrected. GO terms with corrected *P*-value \< 0.05 were considered significantly enriched by DEGs, based on Wallenius non-central hyper geometric distribution. KEGG is a database resource for understanding high-level functions and utilities of the biological system (<http://www.genome.jp/kegg/>) ([@ref-14]). Each KEGG pathway will be considered as a unit gene set. And geometric test will interrogate significantly enriched pathway based on background genes and DEGs list. We used KOBAS (2.0) software ([@ref-19]) to test the statistical enrichment of differential expression genes in KEGG pathways, and corrected *P*-value \<0.05 were considered significantly enriched by DEGs.

Quantitative PCR
----------------

Total RNAs were reverse transcribed using First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's instructions, and were used for quantitative PCR with SYBR Green master mix on an ABI PRISM 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) as previously described ([@ref-39]). Gene specific primers were designed using Primer3 software32 ([Tables S1](#supp-1){ref-type="supplementary-material"}--[S4](#supp-1){ref-type="supplementary-material"}). In addition, reverse transcription-polymerase chain reaction (RT-PCR) primer for EGFR was as follows: forward: 5′-ATCACAATCAGCCCCTGCAT-3′ and reverse 5′-TGCCATTTGGCTTGGTTTCC-3′. Quantitative data were normalized to GAPDH, and the relative quantity was calculated using the (2^−ddCt^) method.

Statistical analysis
--------------------

Experiments were performed independently at least three times. Numerical data were expressed as the means ± SD. Statistical analysis was performed using SPSS 19 software. Differences between two groups were assessed using a Student's *t*-test. *P*-value \< 0.05 was considered to be statistically significant difference.

Results
=======

EGFR inhibition hinders proliferation of mESCs by inducing cell cycle arrest at G~0~/G~1~ phase
-----------------------------------------------------------------------------------------------

Immunofluorescent staining and RT-PCR results showed that EGFR was expressed in mESCs ([Figs. S1A](#supp-1){ref-type="supplementary-material"} and [S1B](#supp-1){ref-type="supplementary-material"}). CCK-8 assay showed that the cell viability was significantly lower in AG1478 treated mESCs than control cells, which suggests that EGFR deficiency hinders mESCs proliferation ([Fig. 1A](#fig-1){ref-type="fig"}). To address how EGFR affects mESCs proliferation, we analyzed cell cycle distribution of AG1478 treated mESCs by Flow cytometry analysis. Relative to control mESCs, the proportion of G~0~/G~1~ phase in AG1478 treated mESCs was increased significantly by approximately 81.72%, while the proportion of S phases was decreased significantly by approximately 22.76% ([Figs. 1B](#fig-1){ref-type="fig"} and [1C](#fig-1){ref-type="fig"}). These results suggested that EGFR inhibition could hinder mESCs proliferation by arresting cell cycle at G~0~/G~1~ phase. Quantitative PCR and western-blot were used to examine the expressions of pivotal cell cycle regulatory genes. EGFR-deficient mESCs showed decreased mRNA expressions of CDK2 (decreased 70.2%), CDK4 (decreased 72.5%), and proliferating cell nuclear antigen (PCNA) (decreased 60.3%) ([Fig. 1D](#fig-1){ref-type="fig"}). Meanwhile, EGFR-deficient mESCs showed decreased protein expressions of CDK2 (decreased 11.3%) and PCNA (decreased 25.2%) ([Figs. 1E](#fig-1){ref-type="fig"} and [1F](#fig-1){ref-type="fig"}). Thus, EGFR inhibition by AG1478 arrested mESCs cell cycle at G~0~/G~1~ phase through altering the expression of pivotal cell cycle regulatory genes.

![Inhibition of EGFR by AG1478 hinders mESCs proliferation and induces cell cycle arrest at G~0~/G~1~ phase.\
(A) Control and AG1478 treated mESCs were compared for cell viability by CCK-8. (B and C) Cell cycle phase distribution of control and AG1478 treated mESCs. (D) Quantitative PCR analysis of mRNA levels of cell cycle regulatory genes in control and AG1478 treated mESCs. The amounts of each mRNA were normalized to GAPDH mRNA and are shown relative to the amounts of control mESCs (set to 1). (E) Protein expression of cell cycle regulatory genes (CDK2 and PCNA) in control and AG1478 treated mESCs. β-actin served as a loading control. (F) Quantified relative band intensity ratio of CDK2 and PCNA. The data are presented as mean ± SD (*n* = 3; \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, Student's *t*-test).](peerj-07-6314-g001){#fig-1}

EGFR deficiency impairs mESC self-renewal and pluripotency and drives mESC differentiation
------------------------------------------------------------------------------------------

Epidermal growth factor receptor inhibition resulted in a dramatic reduction in the number and size of AP positive mESC colonies ([Fig. 2A](#fig-2){ref-type="fig"}), and a decreased expression of stage-specific embryonic antigen 1 (SSEA-1) on mESC surface ([Fig. 2B](#fig-2){ref-type="fig"}). The reduction in the immunoreactivity of two pluripotency markers implied the reduced pluripotency state and impaired self-renewal in EGFR-inhibited cells. EGFR inhibition also reduced the expression of pluripotency factors like OCT4 (decreased 51.5% in mRNA level, and decreased 26.9% in protein level) and Nanog (decreased 67.5%) ([Figs. 2C](#fig-2){ref-type="fig"}--[2E](#fig-2){ref-type="fig"},[2G](#fig-2){ref-type="fig"} and [2H](#fig-2){ref-type="fig"}), and impaired pluripotency protection network composed of several key factors including Lin28b (decreased 38.2%) and PRDM14 (decreased 85.7%) ([Fig. 2E](#fig-2){ref-type="fig"}), suggesting that EGFR is necessary for maintaining mESC pluripotency. To investigate whether EGFR inhibition would induce mESC differentiation, we examined the expression levels of early differentiation markers by quantitative PCR and western-blot ([Figs. 2F](#fig-2){ref-type="fig"}--[2H](#fig-2){ref-type="fig"}). As a result, EGFR inhibition led to an increase in the mRNA levels of three germ layer markers including Notch1 (increased 3.7-fold), Nestin (increased 4.0-fold), and Pax6 (increased 3.1-fold) ([Fig. 2F](#fig-2){ref-type="fig"}), suggesting that EGFR inhibition drives mESC differentiation. EB formation reflects the pluripotency of mESCs. Here, we found that EB formation failed in mESCs after EGFR inhibition by AG1478, confirming the impairment of pluripotency in EGFR inhibited mESCs ([Fig. 2I](#fig-2){ref-type="fig"}).

![Inhibition of EGFR by AG1478 impairs mESC self-renewal and pluripotency, and induces differentiation.\
(A) Enzymatic activity for AP was analyzed in control and AG1478 treated mESCs. (B--D) IF staining against SSEA-1 (red), OCT-4 (green), and Nanog (red) in control and AG1478 treated mESCs. Nuclei were counterstained by 4′,6-diamidino-2-phenylindole, scale bar: 200 μm. (E and F) Quantitative PCR analysis of mRNA levels of pluripotency factor s and differentiation related genes in control and AG1478 treated mESCs. The amounts of each mRNA were normalized to GAPDH mRNA and are shown relative to the amounts in control mESCs (set to 1). (G) Protein expression of OCT4 and GATA4 in control and AG1478 treated mESCs. β-actin served as a loading control. (H) Quantified relative band intensity ratio of OCT4 and GATA4. The data are presented as mean ± SD (*n* = 3; \*\**P* \< 0.01, \*\*\**P* \< 0.001, Student's *t*-test). (I) The performance of EB formation of control and AG1478 treated mESCs, scale bar: 100 μm.](peerj-07-6314-g002){#fig-2}

Gefitinib and RNA interference induced similar gene expression changes as AG1478 treatment in mESCs
---------------------------------------------------------------------------------------------------

To rule out the possibility of non-specific effects of AG1478, we also used another EGFR inhibitor (gefitinib) and RNA interference assay to analyze the proliferation, differentiation, and expression of pluripotency markers of mESCs. Five μM was selected as the suitable concentration to inhibit EGFR phosphorylation activity ([Fig. S3A](#supp-1){ref-type="supplementary-material"}). EGFR inhibition by gefitinib in mESCs markedly reduced protein expressions of the cell cycle regulatory genes (CDK2 (decreased 20.1%) and CDK4 (decreased 64.1%)). The protein expression of pluripotency factors (OCT4 (decreased 52.9%)) also dramatically decreased, while the differentiation related genes (GATA4 (increased 2.1-fold) and Notch1 (increased 1.2-fold)) were up-regulated in mESCs after EGFR inhibition ([Figs. 3A](#fig-3){ref-type="fig"} and [3B](#fig-3){ref-type="fig"}). Four siRNA oligonucleotides were prepared and EGFR expression was knocked down after RNA interference ([Fig. S3B](#supp-1){ref-type="supplementary-material"}). Western-blot detection revealed that the protein expressions of CDK2 (decreased 20.0%) and OCT4 (decreased 41.2%) were reduced, while the protein expressions of GATA4 (increased 1.5-fold) and Notch1 (increased 1.2-fold) were elevated in mESCs by silencing of the EGFR with siRNA-3 ([Figs. 3C](#fig-3){ref-type="fig"} and [3D](#fig-3){ref-type="fig"}). These genes were related to cell cycle, self-renewal, pluripotency, and differentiation. The effects observed by EGFR inhibition with another inhibitor gefitinib and siRNA were consistent with those observed by AG1478 treatment in mESCs. Thus, we further confirmed the on-target effects of AG1478 on mESCs including cell cycle progress, self-renewal and pluripotency through EGFR impairment.

![Inhibition of EGFR by gefitinib and RNA interference impairs mESCs cell cycle and self-renewal related genes expression.\
(A) Protein expression of cell cycle regulatory genes (CDK2 and CDK4), pluripotency factor (OCT4), and differentiation related genes (GATA4 and Notch1) in control and gefitinib treated mESCs. β-actin served as a loading control. (B) Quantified relative band intensity ratio of A. (C) Protein expression of cell cycle regulatory genes (CDK2), pluripotency factor (OCT4), and differentiation related genes (GATA4 and Notch1) in mESCs after RNA interference with different siRNAs. β-actin served as a loading control. (D) Quantified relative band intensity ratio of C. The data are presented as mean ± SD (*n* = 3; \**P* \< 0.05, \*\**P* \< 0.01, Student's *t*-test).](peerj-07-6314-g003){#fig-3}

EGFR inhibition causes transcriptional changes involved in self-renewal and pluripotency
----------------------------------------------------------------------------------------

We sequenced cDNA libraries from three AG1478 treated mESCs samples (numbered as Treat 1, Treat 2, and Treat 3) and three control mESCs samples (numbered as Control 1, Control 2, and Control 3). In total, 746,337,642 raw reads were acquired with an error rate 0.02%, and then 734,603,314 clean reads were generated from raw reads ([Table S5](#supp-1){ref-type="supplementary-material"}). Approximately 611,878,157 clean reads were mapped to the mouse genome mm10, and the alignment percentage for each sample was more than 81.24%. The percentage of uniquely mapped reads was more than 69.32% for each sample ([Table S6](#supp-1){ref-type="supplementary-material"}). The Pearson correlation coefficients of gene expression levels were greater than 0.95 in both EGFR inhibited group and the control group ([Fig. S1C](#supp-1){ref-type="supplementary-material"}), demonstrating the similarity of expression within one group, the rationality of samples selection, and the reliability of sequencing data.

The expression profiling showed global significant changes in gene expression between two mESCs groups. 5,231 genes were considered as significant differentially expressed with corrected *P*-value \<0.05, including mRNAs and lncRNAs. Among them, 1,811 genes were up-regulated and 3,420 genes were down-regulated in response to EGFR inhibition ([Fig. 4A](#fig-4){ref-type="fig"}). And the transcription changes of mRNAs were analyzed in the present article. Quantitative PCR validation results of nine randomly selected genes were consistent with RNA-seq data, which are related to cell cycle (Sfn, Cdc20, Rab11a), p53 signaling pathway (Sfn), ribosome (Pramef17, Klf6), citrate cycle (TCA cycle) (Tdh), and oxidative phosphorylation (Ddit4) ([Fig. 4B](#fig-4){ref-type="fig"}). Through GO survey, we observed several self-renewal and pluripotency associated terms, such as cell cycle, apoptotic process, stem cell maintenance, condensed chromosome, chromatin binding, histone binding, and transcription factor binding ([Table 1](#table-1){ref-type="table"}). As determined by KEGG analysis, many DEGs were enriched in pathways related to self-renewal and pluripotency such as cell cycle, p53 signaling pathway, ribosome, Citrate cycle (TCA cycle), and oxidative phosphorylatio ([Fig. 4C](#fig-4){ref-type="fig"}; [Table 2](#table-2){ref-type="table"}).

![Differentially expressed genes and KEGG pathway enrichment.\
(A) Volcano plot of the identified genes in all biological replicates (the genes that showed significant down- and up-regulated after statistical analysis are reported in green and red). (B) Validation of RNA-Seq data by quantitative PCR. Each gene was normalized to GAPDH. Data are presented as the log~2~ fold change between EGFR inhibition and control mESCs. (C) Scatter plot of top 20 KEGG enrichments of mRNA. Vertical coordinate represents pathway name, and horizontal coordinate represents Rich factor. The size and color of points represent the number of differentially expressed genes in the pathway and the range of different corrected *P*-values, respectively.](peerj-07-6314-g004){#fig-4}
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###### Self-renewal and pluripotency related GO categories significantly enriched from DEGs between two mESCs groups.

![](peerj-07-6314-g005)

![](peerj-07-6314-g006)

  GO ID          GO category          Description                                            Corrected *P*-value
  -------------- -------------------- ------------------------------------------------------ ---------------------
  <GO:0007049>   Biological process   Cell cycle                                             3.14*E*-53
  <GO:0000075>   Biological process   Cell cycle checkpoint                                  3.75*E*-13
  <GO:0022403>   Biological process   Cell cycle phase                                       1.75*E*-05
  <GO:0044770>   Biological process   Cell cycle phase transition                            3.22*E*-19
  <GO:0022402>   Biological process   Cell cycle process                                     2.51*E*-48
  <GO:0000278>   Biological process   Mitotic cell cycle                                     3.99*E*-38
  <GO:0007093>   Biological process   Mitotic cell cycle checkpoint                          2.01*E*-08
  <GO:0044772>   Biological process   Mitotic cell cycle phase transition                    3.55*E*-16
  <GO:0045786>   Biological process   Negative regulation of cell cycle                      0.001747
  <GO:1901988>   Biological process   Negative regulation of cell cycle phase transition     1.72*E*-12
  <GO:0010948>   Biological process   Negative regulation of cell cycle process              2.93*E*-11
  <GO:0051726>   Biological process   Regulation of cell cycle                               7.67*E*-20
  <GO:1901987>   Biological process   Regulation of cell cycle phase transition              1.06*E*-16
  <GO:0007346>   Biological process   Regulation of mitotic cell cycle                       2.24*E*-09
  <GO:1901990>   Biological process   Regulation of mitotic cell cycle phase transition      9.37*E*-13
  <GO:0000082>   Biological process   G1/S transition of mitotic cell cycle                  0.000163
  <GO:1901989>   Biological process   Positive regulation of cell cycle phase transition     0.003147
  <GO:0090068>   Biological process   Positive regulation of cell cycle process              0.000392
  <GO:0006915>   Biological process   Apoptotic process                                      2.38*E*-13
  <GO:0042981>   Biological process   Regulation of apoptotic process                        2.31*E*-07
  <GO:0097190>   Biological process   Apoptotic signaling pathway                            2.77*E*-11
  <GO:0043066>   Biological process   Negative regulation of apoptotic process               0.0034509
  <GO:0019827>   Biological process   Stem cell maintenance                                  0.012077
  <GO:0032153>   Cellular component   Cell division site                                     0.0080312
  <GO:0032155>   Cellular component   Cell division site part                                0.0080312
  <GO:0000793>   Cellular component   Condensed chromosome                                   1.28*E*-16
  <GO:0000777>   Cellular component   Condensed chromosome kinetochore                       2.33*E*-05
  <GO:0000779>   Cellular component   Condensed chromosome, centromeric region               1.56*E*-07
  <GO:0000794>   Cellular component   Condensed nuclear chromosome                           1.62*E*-06
  <GO:0000780>   Cellular component   Condensed nuclear chromosome, centromeric region       0.00080836
  <GO:0000123>   Cellular component   Histone acetyltransferase complex                      0.00053467
  <GO:0035097>   Cellular component   Histone methyltransferase complex                      3.66*E*-06
  <GO:0044429>   Cellular component   Mitochondrial part                                     1.04*E*-42
  <GO:0005720>   Cellular component   Nuclear heterochromatin                                0.00039438
  <GO:0031519>   Cellular component   PcG protein complex                                    0.008405
  <GO:0005912>   Cellular component   Adherens junction                                      1.40*E*-13
  <GO:0003682>   Molecular function   Chromatin binding                                      2.39*E*-08
  <GO:0031490>   Molecular function   Chromatin DNA binding                                  0.0025282
  <GO:0042393>   Molecular function   Histone binding                                        8.38*E*-08
  <GO:0032453>   Molecular function   Histone demethylase activity (H3-K4 specific)          0.037622
  <GO:0004402>   Molecular function   Histone acetyltransferase activity                     0.019528
  <GO:0046972>   Molecular function   Histone acetyltransferase activity (H4-K16 specific)   0.015756
  <GO:0043995>   Molecular function   Histone acetyltransferase activity (H4-K5 specific)    0.015756
  <GO:0043996>   Molecular function   Histone acetyltransferase activity (H4-K8 specific)    0.015756
  <GO:0008134>   Molecular function   Transcription factor binding                           0.0044703

**Notes:**

The details of the table are described below: (1) GO ID: the unique id in gene ontology database; (2) GO category: type of the GO term (cellular component, biological process, or molecular function); (3) description: function description in gene ontology; (4) corrected *P*-value: statistical significance on enrichment with correction.
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###### Self-renewal and pluripotency related KEGG pathways significantly enriched from DEGs between two mESCs groups.

![](peerj-07-6314-g007)

  KEGG ID    KEGG term description               Corrected *P*-value
  ---------- ----------------------------------- ---------------------
  mmu04110   Cell cycle                          6.98*E*-06
  mmu04115   p53 signaling pathway               0.008629188
  mmu03030   DNA replication                     1.73*E*-05
  mmu03010   Ribosome                            5.67*E*-08
  mmu03008   Ribosome biogenesis in eukaryotes   2.00*E*-07
  mmu03040   Spliceosome                         7.14*E*-11
  mmu03015   mRNA surveillance pathway           0.000343
  mmu03013   RNA transport                       1.66*E*-10
  mmu03018   RNA degradation                     0.001903
  mmu01100   Metabolic pathways                  2.00*E*-07
  mmu00240   Pyrimidine metabolism               1.25*E*-05
  mmu00190   Oxidative phosphorylation           4.13*E*-06
  mmu00020   Citrate cycle (TCA cycle)           0.001666
  mmu01200   Carbon metabolism                   3.66*E*-05

**Notes**:

The details of the table are described below: (1) KEGG ID: unique pathway id in the KEGG database; (2) KEGG term description: function description of the KEGG pathway; (3) Corrected *P*-value: statistical significance of the enrichment with correction.

Discussion
==========

In current study, the effects of EGFR deficiency on mESCs self-renewal and pluripotency were investigated through its inhibition by AG1478 and bioinformatics analysis of RNA-seq. The results demonstrated the importance of EGFR in maintaining proliferation, self-renewal, and pluripotency of mESCs.

Self-renewal entails fast cell division with a concomitant differentiation suppression, and pluripotency is indispensably associated with this competency of self-renewal. Rapid division of mESCs is associated with a truncated G~1~ phase in cell cycle ([@ref-23]). After EGFR inhibition by AG1478, cell cycle of mESCs was significantly arrested at G~0~/G~1~ phase. Expressions of pivotal cell cycle regulatory genes were decreased in EGFR deficient mESCs. The transition from G~1~ phase to S phase were accelerated by CDK2 and CDK4, which formed complex with cyclin E and cyclin D, respectively ([@ref-23]), and their expressions were down-regulated after EGFR inhibition. Consistent with the decreased cell viability and S phase length, the expression of PCNA which plays key roles in DNA replication, chromatin remodeling, DNA repair, and cell cycle regulation ([@ref-37]) was decreased in EGFR deficient mESCs. GO analysis in EGFR deficient mESCs revealed that many DEGs could be categorized into cell cycle and proliferation related terms, such as cell division site, cell cycle phase transition, and regulation of apoptotic process. Consistently, KEGG enrichment analysis indicated that DEGs were mainly involved in cell cycle and proliferation related pathways, such as cell cycle, DNA replication, and p53 signaling pathway. These gene expression changes may arrested cell cycle at G~0~/G~1~ phase in EGFR deficient mESCs. Thus, EGFR is indispensable in maintaining proliferation and promoting cell cycle progress in mESCs.

Pluripotency factors, such as OCT4, Nanog, and SOX2, are exclusively expressed in undifferentiated mESCs, and play central roles in protecting mESCs self-renewal from differentiation. Once their expressions are decreased, stem cells irresistibly switch from self-renewal to differentiation ([@ref-9]; [@ref-33]; [@ref-49]). The critical roles of pluripotency factors in self-renewal have been demonstrated by the previous results of pluripotency cells researches and induced pluripotent stem cell researches ([@ref-22]; [@ref-40]). In our study, expressions of pluripotency factors were dramatically down-regulated in EGFR deficient mESCs, accompanied by decreased expressions of pluripotency markers AP and SSEA-1 as well as increased expressions of early differentiation marker genes, indicating an impairment of self-renewal and occurrence of differentiation in EGFR deficient mESCs. It is well known that LIF plays critical roles in maintaining the self-renewal and pluripotency of mESCs in vitro ([@ref-3]; [@ref-25]) and Tfcp2l1 was reported as a mediator sensitive to the stimulus of LIF/STAT3 pathway ([@ref-46]). We found that Tfcp2l1 expression was dramatically down-regulated in mESCs with EGFR defect, which led to the proposal that there might be lack of mediators to convey extraneous self-renewal stimulus to expression of pluripotency factors. Moreover, the failure of EB formation demonstrated a completely loss of pluripotency in EGFR-inhibited mESCs. Taken together, EGFR deficiency impaired self-renewal and pluripotency in mESCs through decreasing expressions of pluripotency factors.

For better understanding how EGFR inhibition impaired mESCs pluripotency, the transcriptome profiling was performed. Later, the GO analysis showed that significantly enriched GO terms were associated with self-renewal and pluripotency, such as cell cycle, stem cell maintenance, condensed chromosome, chromatin binding, and transcription factor binding. Accordingly, KEGG analysis indicated that DEGs were mainly enriched in pathways of cell cycle, p53 signaling pathway, DNA replication, ribosome, and metabolic regulation. These pathways are related to self-renewal or differentiation initiation. Bioinformatics analysis revealed that EGFR is necessary for self-renewal and pluripotency in mESCs from various aspects, including cell cycle, chromatin structure, epigenetic modification, and metabolic process.

In our study, we found that a switch from self-renewal to differentiation in EGFR-deficient cells. This phenomenon revealed that EGFR is critical for maintaining self-renewal and pluripotency of mESCs. Meanwhile, EGFR inhibition by AG1478 treatment in mESCs markedly reduced cell proliferation, caused cell cycle arrest at G~0~/G~1~ phase, and altered protein expressions of the cell cycle regulatory genes. Zhu et al. reported that cell cycle arrest in G~1~ phase in CNE2 cells induced by AG1478 may be associated with a significant up-regulation of p27 protein levels ([@ref-52]). It has been recently proposed that AG1478 might have EGFR-independent activity in disassembling the Golgi in human cells, through inhibiting the activity of a small GTPase ADP-ribosylation factor ([@ref-2]). Therefore, we also need to perform more mechanism studies underlying EGFR function to further elucidate its role in the proliferation, self-renewal, and pluripotency of mESCs.

Conclusions
===========

Collectively, using the AG1478 inhibition model and RNA-seq analysis, we discovered the importance of EGFR in self-renewal and pluripotency through regulating cell cycle and the expression of pluripotency factors. As a cell surface receptor conveying exogenous stimulations, EGFR deficiency led to cell cycle arrest, and impaired self-renewal and pluripotency. These findings will improve our understanding of the molecular mechanisms driving the self-renewal and pluripotency of mESCs.
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